XClose

RESEARCH DOMAINS

PERSONALISED MEDICINE

Home bam
Menu

Personalised Medicine Viewer

Pain sensors specialised for specific sensations

Many pain-sensing nerves in the body are thought to respond to all types of ‘painful events’, but new UCL research in mice reveals that in fact most are specialised to respond to specific types such as heat, cold or mechanical pain.

Publication date:

‘Middle England’ faces lowest psychosis risk

The risk of developing a psychotic disorder such as schizophrenia is highest for young people, men, ethnic minorities and people living in urban areas and poorer neighbourhoods, finds a new study by UCL and the University of Cambridge.

Publication date:

UCL receives largest share of NHS research funding

UCL’s three biomedical research centres (BRCs) have won more than £167 million in funding from the National Institute for Health Research (NIHR) to further world-leading biomedical research conducted with partner hospitals. UCL has received more funding than any other UK university, followed by King's College London and Oxford University, which received £133m and £127m respectively.

Publication date:

Science begins in the new Francis Crick Institute building

The first scientists have moved into the new £650 million Francis Crick Institute building in London and are starting work in their purpose-built labs. Next to St Pancras station and the British Library, the Crick will be the biggest biomedical research institute under one roof in Europe.

Publication date:

Refining the genetic causes of schizophrenia

An international study involving UCL has made advances in understanding the ways in which genetic risk factors alter gene function in schizophrenia.

Publication date:

Heart drug could reduce diabetes related blindness

Researchers at UCL and Queen’s University Belfast have discovered that a drug originally developed to treat cardiovascular disease has the potential to reduce diabetes related blindness.

Publication date:

Cancer drugs could target autoimmune diseases

Drugs currently being trialled in cancer patients have been used to successfully target an autoimmune condition in mice at UCL and King’s College London.

Publication date:

New team to develop radiotherapies that target cancer more effectively

Safer precision radiotherapies that will be able to cure more cancers with fewer side-effects will be available within five years under ambitious new plans for research and treatment at the UCL Cancer Institute and University College London Hospitals (UCLH) NHS Foundation Trust.

Publication date:

Cancer drug could treat blood vessel deformities

A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin, finds new research in mice led by UCL, Memorial Sloan Kettering (MSK) Cancer Center in New York and the Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona.

Publication date:

New drug shows promise against muscle wasting disease

A new drug to treat the muscle wasting disease inclusion body myositis (IBM) reverses key symptoms in mice and is safe and well-tolerated in patients, finds a new study led by the Medical Research Council (MRC) Centre for Neuromuscular Diseases at UCL and the University of Kansas Medical Center.

Publication date:

Tumours contain the seeds of their own destruction

Scientists at UCL have made a groundbreaking discovery in understanding how the genetic complexity of tumours can be recognised and exploited by the immune system, even when the disease is at its most advanced stages.

Publication date:

Resistance to key HIV drug ‘concerningly common’

HIV drug resistance to tenofovir, an antiretroviral drug vital to most modern HIV treatment and prevention strategies, is surprisingly and worryingly common according to a large study led by UCL and funded by the Wellcome Trust.

Publication date:

Early chemotherapy improves survival for men with prostate cancer

Two papers from UCL show that having early chemotherapy improves survival for men with prostate cancer. The papers, published in the Lancet and Lancet Oncology, report the results from the STAMPEDE clinical trial and a meta-analysis.

Publication date:

Improving treatment for systemic amyloidosis

A potential new approach to treat systemic amyloidosis, invented at UCL and being developed by GlaxoSmithKline (GSK), marks the start of a successful and innovative academic-industry collaboration.

Publication date:

UCL to coordinate £16m project to crack difficult disease areas

UCL has successfully coordinated a £16 million bid to work with the Medical Research Council (MRC), GSK and four other universities to improve scientists’ understanding of inflammatory and fibrotic diseases that present a serious burden to patients.

Publication date:

Many overweight teenagers do not recognise they are too heavy

More than a third of overweight or obese teenagers don’t see themselves as being too heavy and think their weight is about right, according to a UCL study published today in the International Journal of Obesity.

Publication date:

New treatment for polycystic kidney disease

A new technique for treating polycystic kidney disease has been identified by researchers based at the UCL Institute of Child Health. Published in the Journal of the American Society of Nephrology, the treatment, which involves targeting tiny blood and lymphatic vessels inside the kidneys, is shown to improve renal function and slow progression of disease in mice.

Publication date: